AssetMark’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
AssetMark's SRPT Position: Q3 2026 in Review
AssetMark reduced its Sarepta Therapeutics (SRPT) stake by 4.8% in Q3 2026, selling an estimated $599 and leaving 640 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.
AssetMark first reported a position in SRPT in Q2 2023 and has held it in 14 quarters since. The position peaked at $5.2M in Q4 2024. 235 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.
- AssetMark held 640 shares of Sarepta Therapeutics worth $11.7K as of Q3 2026.
- AssetMark sold 32 Sarepta Therapeutics shares in Q3 2026, an estimated $599.
- Sarepta Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #2448 holding.
- AssetMark first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 14 quarters since.
- AssetMark's Sarepta Therapeutics position peaked at $5.2M in Q4 2024.
- 235 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.